GlassScriptPhysician profile
Thu N Tran
NPI 1003807363
$2,001.93
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $215 · 2021: $336 · 2022: $426 · 2023: $404 · 2024: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.01 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $172.30 | 2019-2024 | |
| Astellas Pharma US INC | $159.46 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $108.48 | 2021-2023 | |
| Caldera Medical, INC | $101.94 | 2024 | Desara |
| Bayer Healthcare Pharmaceuticals INC. | $99.59 | 2019-2023 | |
| Allergan, INC. | $94.17 | 2019-2020 | |
| Aspira Women'S Health INC | $92.54 | 2019-2022 | |
| Exact Sciences Corporation | $84.88 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $79.00 | 2022-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $78.51 | 2019-2024 | Gardasil 9, Gardasil |
| Therapeuticsmd, INC. | $69.50 | 2019-2022 | |
| Coopersurgical, INC. | $48.69 | 2022-2023 | Paragard T 380a |
| Amag Pharmaceuticals, INC. | $44.34 | 2019-2020 | |
| Sage Therapeutics, LLC | $34.00 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $29.82 | 2020 | |
| Avion Pharmaceuticals | $26.95 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $25.85 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $22.97 | 2020 | |
| Hologic Sales and Service, LLC | $22.48 | 2022 | |
| Myovant Sciences INC. | $20.65 | 2022 | |
| Exeltis, USA INC. | $20.03 | 2022 | |
| Mylan Pharmaceuticals INC. | $19.45 | 2022 | |
| Smith+Nephew, INC. | $16.73 | 2019 | |
| Sanofi Pasteur INC. | $16.68 | 2019 | |
| Daiichi Sankyo INC. | $15.91 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.